GlassScriptPhysician profile
Amy Reynolds
NPI 1255952123
$6,318.36
in general payments reported to CMS, 2019-2025
32 companies · $351 in 2025
The $351 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,441 · 2022: $1,793 · 2023: $1,285 · 2024: $448 · 2025: $351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,084.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,083.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,009.96 | 2021-2025 | |
| Corcept Therapeutics | $780.91 | 2021-2025 | Korlym |
| Lilly USA, LLC | $739.98 | 2021-2024 | Mounjaro, Trulicity, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $468.65 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $454.00 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $420.36 | 2021-2022 | |
| Novo Nordisk INC | $325.23 | 2021-2023 | Ozempic, Rybelsus |
| Antares Pharma, INC. | $286.35 | 2021-2024 | Xyosted |
| Medtronic, INC. | $285.91 | 2021-2025 | Minimed 780g |
| Merck Sharp & Dohme LLC | $245.30 | 2021-2023 | Steglatro, Steglujan, Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $217.23 | 2021-2022 | |
| Mannkind Corporation | $163.94 | 2022-2023 | Afrezza |
| Amgen INC. | $150.20 | 2021-2022 | |
| Recordati_rare_diseases_inc. | $121.73 | 2022-2025 | Isturisa, Signifor Lar |
| Astellas Pharma US INC | $109.13 | 2025 | Veozah |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $83.96 | 2021-2023 | Unithroid |
| Tandem Diabetes Care, INC. | $72.93 | 2021-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Insulet Corporation | $44.47 | 2021-2025 | Omnipod |
| Biohaven Pharmaceuticals, INC. | $43.59 | 2021 | |
| Xeris Pharmaceuticals, INC. | $40.67 | 2021 | |
| Dexcom, INC. | $38.42 | 2021 | |
| Exact Sciences Corporation | $27.05 | 2023-2024 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $26.15 | 2024 | Rexulti |
| Halozyme INC | $23.72 | 2023 | |
| Cequr Corporation | $22.27 | 2023 | Cequr Simplicity |
| Clarus Therapeutics INC. | $20.33 | 2021 | |
| Lundbeck LLC | $20.10 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.28 | 2022 | |
| Eusa Pharma (US) LLC | $16.55 | 2022 | |
| Acella Pharmaceuticals, LLC | $15.02 | 2024 | NP Thyroid 60 |
| Ultragenyx Pharmaceutical INC. | $15.00 | 2022 | |
| Nestle Healthcare Nutrition INC. | $11.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Reynolds listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.